HER2 ADCs in Gynecologic Cancers

CME

Emerging HER2-Targeted Antibody–Drug Conjugates in Gynecologic Cancers

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: May 09, 2024

Expiration: November 08, 2024

Kathleen N. Moore
Kathleen N. Moore, MD, MS, FASCO

Activity

Progress
1
Course Completed

Introduction

In this activity, Kathleen N. Moore, MD, MS, reviews recent developments in HER2 testing, appraises clinical trial results for anti-HER2 antibody–drug conjugate (ADC) therapy, and discusses current strategies for managing the safety profile of anti-HER2 ADCs in patients with gynecologic cancers.

Please note that the slide thumbnails in this activity link to a PowerPoint slideset, which also can be found here. The slideset also may be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options intends to measure the educational impact of this activity. A few questions will be asked twice: Once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with gynecologic cancers (eg, cervical, endometrial, and ovarian cancer) do you provide care for in a typical month?

The phase II DESTINY-PanTumor02 trial evaluated trastuzumab deruxtecan (T-DXd) monotherapy in patients with advanced HER2-positive solid tumors who were not eligible for curative treatment and progressed after prior therapy or were without satisfactory alternative therapy options. Which of the following efficacy results were reported for T-DXd in the patient population with gynecologic cancer?

Which of the following would you recommend for a patient receiving T-DXd for recurrent HER2-positive endometrial cancer who develops treatment-related asymptomatic grade 1 pneumonitis?